Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$10.98
-$0.59(-1.49%)
At close: 4:00 PM EST
$10.98
-$0.59(-1.49%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume146.24K
Average Volume (3M)3.01M
Market Cap
$2.38B
Enterprise Value$1.45B
Total Cash (Recent Filing)$347.82M
Total Debt (Recent Filing)$286.18M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 03, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding150,560,990
10 Day Avg. Volume3,906,047
30 Day Avg. Volume3,005,098
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-704.59
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$17.64Price Target Upside60.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Opakalim Clinical Data And Planned Pivotal ReadoutsDifferentiated efficacy and low CNS side effects in proof-of-concept data validate opakalim's mechanism and de-risks progression to pivotal trials. Successful Phase 2/3 readouts would create a durable commercial opportunity in refractory focal epilepsy and strengthen Biohaven's CNS product portfolio.
Shareholder Support For Board, Auditor, And Executive PayStrong shareholder votes reinforce governance continuity and management mandate, reducing risk of disruptive leadership changes. Stable board and auditor relationships support consistent strategic execution and oversight, aiding medium-term program planning and credibility with partners and investors.
Expanded At-the-market Equity Program Increases Financing FlexibilityAccess to an ATM program provides structural financing optionality to fund trials and operations without a single dilutive event. Opportunistic issuance smooths capital raises, helping sustain R&D timelines and trial execution through the next 2-6 months as pivotal readouts approach.
Bears Say
Zero Revenue With Large Recurring Net LossesNo commercial revenue and persistent multihundred-million-dollar losses mean the company lacks internal earnings to fund operations. Over the medium term this necessitates continued financing, increases stakeholder uncertainty, and limits reinvestment capacity absent successful product launches.
Deep Negative Operating And Free Cash FlowSustained heavy cash burn erodes runway and forces reliance on capital markets or dilution. Cash-negative operations constrain flexibility to scale late-stage trials or commercial launches, making program continuity and milestone timing contingent on successful financing execution.
Materially Higher Leverage And Weakened Equity BaseA sharp rise in debt and collapsing equity raises financial risk, limits borrowing capacity, and may increase cost of capital. Elevated leverage reduces resilience to setbacks, tightens covenant and liquidity constraints, and can hamper long-term strategic optionality if markets deteriorate.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.38B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Aug 03, 2026 which is in 35 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on May 04, 2026. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.831 by -$0.049.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.75.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 150,560,990 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.831. Following the earnings report the stock price went down -4.241%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.64 (60.62% Upside)
$17.64 (60.62% Upside)
Blogger Sentiment
Neutral
BHVN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.39%
12-Months-Change
Fundamentals
Return on Equity
-866.46%
Trailing 12-Months
Asset Growth
1.63%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
BHVN Stock 12 Month Forecast
Average Price Target
$17.64
▲(60.62% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
11.98% Mutual Funds
33.60% Other Institutional Investors
33.80% Public Companies and
Individual Investors